ATM Inhibition Drives Metabolic Adaptation via Macropinocytosis

Study Background and Research Question

Ataxia-telangiectasia mutated (ATM) kinase is a well-established regulator of the DNA damage response, acting as a tumor suppressor and orchestrating cellular repair after genotoxic stress. Beyond DNA repair, ATM is increasingly recognized for its role in metabolic regulation and adaptation, particularly in cancer. Macropinocytosis—a nonselective form of endocytosis—enables cancer cells to scavenge extracellular nutrients under metabolic stress, supporting tumor growth and survival. However, the relationship between ATM inhibition and macropinocytosis, especially how this interaction impacts cancer cell metabolism and survival, has remained unclear.

The central question addressed by Huang et al. (2023) is whether suppression of ATM kinase activity can drive metabolic adaptation in cancer cells by inducing macropinocytosis, thus promoting cell survival under nutrient-deprived conditions. Furthermore, the authors aim to identify if this adaptation creates a new metabolic vulnerability that could be therapeutically exploited.

Key Innovation from the Reference Study

The key innovation of this work is the demonstration that ATM inhibition robustly enhances macropinocytosis, which in turn supports the survival and proliferation of cancer cells in environments with limited nutrients. The study further reveals that this adaptation increases the uptake of branched-chain amino acids (BCAAs), which are critical for cell growth. Crucially, the combination of ATM inhibition with pharmacological blockade of macropinocytosis leads to synthetic lethality—effectively suppressing tumor cell proliferation and inducing cell death both in vitro and in vivo. This integrated approach unveils a previously unrecognized metabolic liability in ATM-inhibited cancer cells.

Methods and Experimental Design Insights

Huang et al. employed a multi-layered experimental design to dissect the link between ATM activity, macropinocytosis, and metabolic adaptation. Key methodologies included:

• Genetic and pharmacological inhibition of ATM kinase in several cancer cell lines, including ovarian cancer models.
• Quantification of macropinocytosis using uptake assays with high-molecular-weight fluorescent dextrans.
• Metabolomic profiling of both cell-intrinsic and tumor microenvironmental amino acid pools, focusing on BCAA dynamics.
• Intervention studies combining ATM inhibition with macropinocytosis inhibitors to assess effects on cell proliferation and survival.
• In vivo validation using mouse xenograft models to test the combinatorial suppression of ATM and macropinocytosis pathways.
• Supplementation experiments where exogenous amino acids or BCAAs were added to ATM-inhibited cells to probe mechanisms.

This integrated approach allowed the authors to map both the metabolic and survival consequences of ATM inhibition, with a particular emphasis on nutrient scavenging strategies adopted by cancer cells.

Core Findings and Why They Matter

Several pivotal findings emerge from the study:

• ATM inhibition increases macropinocytosis: Both pharmacological and genetic suppression of ATM activity led to a marked increase in the internalization of extracellular fluid-phase markers, confirming upregulated macropinocytosis (Huang et al., 2023).
• Enhanced nutrient uptake and metabolic adaptation: ATM-inhibited cells showed increased uptake of BCAAs and other amino acids, supporting proliferation under nutrient-limited conditions. Metabolomic analyses further revealed that ATM-inhibited tumors deplete BCAAs from their microenvironment.
• Synergistic lethality with macropinocytosis blockade: While ATM inhibition alone supports cancer cell survival in low-nutrient environments, its combination with macropinocytosis inhibitors effectively suppresses cell growth and induces apoptosis, both in cultured cells and in animal models.
• BCAA supplementation abrogates macropinocytosis: Adding exogenous BCAAs to ATM-inhibited cells reduced their dependence on macropinocytosis, highlighting a direct metabolic feedback loop.

These findings collectively underscore how ATM kinase not only controls DNA damage response but also orchestrates metabolic resilience via macropinocytosis. Notably, targeting both DNA repair signaling and nutrient scavenging can expose a unique vulnerability in cancers reliant on this adaptation, suggesting a rationale for combination therapies.

Comparison with Existing Internal Articles

The current findings provide a complementary perspective to several internal resources:

• KU-60019: ATM Kinase Inhibitor for Precision Radiosensitization discusses the use of KU-60019 as a potent ATM kinase inhibitor to modulate DNA damage response and radiosensitize cancer cells. The metabolic adaptations described by Huang et al. extend this framework by showing that ATM inhibition also triggers compensatory nutrient uptake mechanisms.
• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cells highlights that ATM inhibition can synergize with metabolic modulators like fenofibrate to induce senescence in ovarian cancer. This aligns with the view that metabolic remodeling is a key vulnerability in ATM-inhibited tumors.
• KU-60019: Selective ATM Inhibitor for Glioma Radiosensiti... further contextualizes KU-60019’s role in profiling metabolic vulnerabilities and DNA damage response inhibition, complementing the mechanistic insights from the Huang et al. study.

Together, these articles suggest that the therapeutic window for ATM kinase inhibitors may be widened by targeting the metabolic dependencies revealed upon ATM inhibition, particularly in cancers with high nutrient demand or impaired DNA repair.

Limitations and Transferability

While the reference study provides strong evidence that ATM inhibition induces macropinocytosis and metabolic adaptation, several limitations should be considered:

• Most experiments were conducted in cell lines or mouse models, which may not fully recapitulate human tumor heterogeneity.
• The metabolic effects of ATM inhibition may differ across cancer types, especially those with varying p53 or c-MYC status, as acknowledged by the authors.
• The safety and feasibility of combined ATM and macropinocytosis inhibition in clinical settings remain to be established.

These findings are most transferable to preclinical research workflows aiming to dissect the interplay between DNA damage response, metabolic adaptation, and nutrient scavenging in cancer.

Protocol Parameters

• ATM kinase inhibition (in vitro): Use 3 μM of a selective ATM inhibitor (such as KU-60019) for cell-based assays to induce DNA damage response inhibition and probe metabolic adaptation mechanisms (product information).
• Macropinocytosis assay: Incubate cells with 70 kDa FITC-dextran (typically 1 mg/mL) for 30–60 minutes at 37°C to quantify fluid-phase uptake.
• BCAA supplementation experiments: Add branched-chain amino acids (e.g., 2 mM each of leucine, isoleucine, and valine) to cell culture media when testing the reversibility of macropinocytic uptake.
• ATM kinase inhibition (in vivo): Deliver 10 μM KU-60019 intratumorally via osmotic pump for mouse xenograft studies, as per established protocols (product information).
• Combination therapy studies: Co-administer ATM inhibitor and an established macropinocytosis inhibitor (e.g., EIPA at 50 μM) to assess synthetic lethality.

Research Support Resources

To facilitate similar investigations into ATM kinase signaling pathway modulation and metabolic adaptation, researchers can utilize KU-60019 (SKU A8336), a potent and selective ATM kinase inhibitor. KU-60019 is suitable for both in vitro and in vivo experiments in cancer research, particularly for studies focused on DNA damage response inhibition, radiosensitization, or metabolic reprogramming workflows. APExBIO provides detailed product information, including solubility guidelines and recommended concentrations, to support protocol optimization.